Posted by Michael Wonder on 26 Oct 2021
Theratechnologies announces reimbursement agreement in Italy for Trogarzo for eligible patients with multi-drug resistant HIV-1
26 October 2021 - Theratechnologies is pleased to announce that it has reached an agreement with the Italian Medicines Agency, AIFA, for the reimbursement of Trogarzo for eligible people aged 18 and older living with multi-drug resistant HIV-1.
A number of patients are also being treated with Trogarzo in other European countries through early access programs. Theratechnologies plans to launch Trogarzo on a country by country basis across Europe as it gains reimbursement in each individual country.
